Certain Options of Agile Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2021.
November 21, 2021
Share
Certain Options of Agile Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2021. These Options will be under lockup for 45 days starting from 8-OCT-2021 to 22-NOV-2021.
Details:
The officers, directors, and certain holders of outstanding capital stock of the company have entered into an lock-up agreement, pursuant to which they will not dispose or hedge shares of common stock or any securities convertible into or exchangeable for shares of common stock for a period of 45 days from the date of the prospectus, without the prior written consent of Oppenheimer & Co. Inc.
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
AGILE THERAPEUTICS, INC. 
